Literature DB >> 19371481

Does chemotherapy have a role before hormone-resistant disease develops?

James P Dean1, Celestia S Higano.   

Abstract

Recent studies have demonstrated a survival benefit for chemotherapy in metastatic hormone-resistant prostate cancer. In other malignancies such as breast or colorectal cancer, use of active chemotherapy regimens earlier in the course of the disease has resulted in improvements in disease-free and overall survival. This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19371481     DOI： 10.1007/s11934-009-0038-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  44 in total

1.  Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer.

Authors:  M Kuriyama; Y Takahashi; M Sahashi; Y Ono; T Tanaka; H Shimizu; S Ohshima
Journal:  Jpn J Clin Oncol       Date:  2001-01       Impact factor: 3.019

2.  Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

Authors:  P E Clark; D M Peereboom; R Dreicer; H S Levin; S B Clark; E A Klein
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

3.  Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.

Authors:  K Pummer; M Lehnert; H Stettner; G Hubmer
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

4.  Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Authors:  Phillip G Febbo; Jerome P Richie; Daniel J George; Massimo Loda; Judith Manola; Sridhar Shankar; Agnieska Szot Barnes; Clare Tempany; William Catalona; Philip W Kantoff; William K Oh
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

5.  Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.

Authors:  Jeremy P Cetnar; S Bruce Malkowicz; Steven C Palmer; Alan J Wein; David J Vaughn
Journal:  Urology       Date:  2008-02-15       Impact factor: 2.649

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Combined hormone-chemotherapy for metastatic prostatic carcinoma. Eleven-year follow-up.

Authors:  C Servadio; M Savion; E Mukamel
Journal:  Urology       Date:  1987-10       Impact factor: 2.649

8.  Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.

Authors:  Masanori Noguchi; Shinshi Noda; Masaki Yoshida; Shoichi Ueda; Taizo Shiraishi; Kyogo Itoh
Journal:  Int J Urol       Date:  2004-02       Impact factor: 3.369

9.  Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer.

Authors:  Avishay Sella; Amnon Zisman; Svetlana Kovel; Nirit Yarom; Dany Leibovici; Arie Lindner
Journal:  Urology       Date:  2008-02       Impact factor: 2.649

10.  Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.

Authors:  D Fontana; O Bertetto; G Fasolis; A Berruti; R Tarabuzzi; G Pagani; T Buniva; R Zolfanelli; S Pallotti; L Frezzotti; C Bumma; S R Rossetti; L Dogliotti
Journal:  Tumori       Date:  1998 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.